Sector
PharmaceuticalsOpen
₹4.45Prev. Close
₹4.25Turnover(Lac.)
₹0.37Day's High
₹4.45Day's Low
₹4.1552 Week's High
₹052 Week's Low
₹0Book Value
₹-59.61Face Value
₹5Mkt Cap (₹ Cr.)
10.53P/E
0EPS
0Divi. Yield
0No Record Found
Y/e 31 Mar( In .Cr) | Jun-2014 | Jun-2013 | Mar-2012 | Mar-2011 |
---|---|---|---|---|
Equity Capital | 12.39 | 12.39 | 12.39 | 18.17 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -133.3 | 6.29 | 169.03 | 136.89 |
Net Worth | -120.91 | 18.68 | 181.42 | 155.06 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Jun-2014 | Jun-2013 | Mar-2012 | Mar-2011 |
---|---|---|---|---|
Revenue | 31.5 | 337.49 | 730.18 | 657.34 |
yoy growth (%) | -90.66 | -53.77 | 11.08 | |
Raw materials | -19.89 | -296.54 | -561.8 | -505.86 |
As % of sales | 63.15 | 87.86 | 76.94 | 76.95 |
Employee costs | -4.81 | -10.12 | -19.98 | -17.67 |
Y/e 31 Mar( In .Cr) | Jun-2014 | Jun-2013 | Mar-2012 | Mar-2011 |
---|---|---|---|---|
Profit before tax | -14.12 | -48.32 | 19.47 | 63.38 |
Depreciation | -4.97 | -6.4 | -5.1 | -3.64 |
Tax paid | 0 | 0 | -0.92 | -13.93 |
Working capital | -120.21 | -141.58 | 55.95 | |
Other operating items |
Y/e 31 Mar | Jun-2014 | Jun-2013 | Mar-2012 | Mar-2011 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -90.66 | -53.77 | 11.08 | |
Op profit growth | -78.72 | -160 | -30.14 | |
EBIT growth | -71.02 | -173.41 | -33.96 | |
Net profit growth | -13.13 | -4,712.22 | -92.88 |
Particulars (Rupees in Crores.) | Jun-2014 | Mar-2012 | Mar-2011 |
---|---|---|---|
Gross Sales | 31.5 | 732.55 | 670.83 |
Excise Duty | 0 | 0 | 0 |
Net Sales | 31.5 | 732.55 | 670.83 |
Other Operating Income | 0 | 0 | 0 |
Other Income | 0 | 1.11 | 3.25 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 129.24 | 4,07,155.15 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 71.05 | 1,47,295.24 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.07 | 1,16,664.33 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 59.03 | 1,07,673.27 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 52.42 | 1,01,358.17 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman
R C Bora
Managing Director
Gopal Ramourti
Executive Director & CFO
N R Bora
Director
A S Chandvankar
Director
M S Raghavan Ayyangar
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Twilight Litaka Pharma Ltd
Summary
Incorporated as a private limited company in Jan.74, Li Taka Pharmaceuticals was converted into a public limited company in Dec.85. Li Taka Laboratories Pvt Ltd was amalgamated with the company in 1986.The company is engaged in the manufacture of various drugs and pharmaceuticals formulations. It also manufactures formulations on loan licence basis as well as on principal to principal basis for various multinational companies like Hindustan Ciba Geigy, Pfizer and Burroughs Wellcome. Its manufacturing facility is located at Pimpri, Pune.The company came out with a rights issue in Apr.92 to meet the long-term working capital requirements of the company and to part-finance its normal capital expenditure including modernisation.In Jun.95, Pegasus Laboratories was amalgamated with the company. The company exported goods worth Rs 1.14 cr in 1996-97.During 1997-98, the company has purchased Marketing division of Borachem Industries Ltd., With this arrangement the companys product will be represented in almost all the major parts of the country. There is a rise of 88.53% in the sales over the previous year. To give more emphasis on own operations the marketing alliance with Smithkline Beecham Pharmaceuticlas (I) Ltd. has been terminated.The company is planning to introduce new products for domestic and internation market.
Read More
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.